Tagged with UAE,

UAE Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US industry is investing in MEA, the challenges presented by the lack of intellectual property enforcement in the region, and the shifting of focus from manufacturing to broader research…

UAE With a relatively high number of genetic disorders, the Arab population of the United Arab Emirates (UAE) is increasingly becoming the subject of new studies. The database from the Center for Arab Genomics Studies indicates the presence of 241 genetic disorders among that demographic, a number they call “extremely high…

UAE Rahja Daher, head of the Health Group for the Swiss Business Council (SBC) Dubai & Northern Emirates discusses the association’s formation, priorities and major challenges, as well as an outline of the healthcare and life sciences sector in the UAE at large.   Dubai is by far still the hub…

Pharma Faces Paolo Carli, head of Middle East, Africa, Turkey, Russia and CIS (MEAR) for Merck has continually taken on greater responsibilities in the Middle East, Africa, Turkey and Eastern Europe. In his most recent interview with PharmaBoardroom, Carli talks strategy, adaptability, and sales growth.    We look at structuring markets with…

UAE Khaled Elrefae, Middle East and Africa Specialty Care Operations Head (GM) for Ipsen, highlights Ipsen’s impressive internationalization strategy and the success factors as well as rationale behind the company entrance to the MEA market with the newly established affiliate in UAE. He then discusses his mandate to drive a transformation…

UAE The United Arab Emirates Genetic Diseases Association (UAEGDA) was established in 2006 and aims to increase awareness programs in order to prevent the occurrence of common genetic disorders in the UAE and throughout the region. Dr. Maryam Matar is the founder of the UAEGDA, and she discusses the importance of…

Merck Since we last met with Paolo Carli in 2013, he has been given greater responsibilities within Merck and is now Head of Middle East, Africa, Turkey, Russia, and CIS countries for the healthcare business. Paolo discusses the logic behind being assigned such a vast region to manage, Merck’s strategy for…

UAE Ana Raposo, country director for Gulf Countries at Janssen discusses her role, the main similarities and differences between the various markets throughout the Gulf, mental health, and corporate social responsibility (CSR) initiatives in the region.   The Gulf markets are very open to innovation and eager to bring the most…

UAE The UAE pharma market is projected to grow over 80 percent by 2027, in part due to a growing demand for the treatment of lifestyle diseases and expansion of comprehensive health insurance.  Made with Visme Presentation Maker     Pharmaceutical imports into the UAE come from 72 countries. 80 percent…

UAE The UAE ranks among the world’s fastest for new drug approvals, ranking first for two cancer drugs and second for many others, such as blockbuster melanoma drug Keytruda. The Ministry of Health and Prevention of the United Arab Emirates (MOHAP) has enhanced its processes by implementing an electronic registration system,…

UAE The UAE ranks as a world leader in rapid drug approvals with its fast-track registration system that accelerates the process and eliminates long waiting times for innovative and orphan drugs.   If you bring innovation, the [UAE] government will support you on all levels Georg Schroeckenfuchs, Novartis In January 2018…

UAE Dubai’s government has announced its ambition to go completely paper-free by the end of the year 2021. Its health authority has recently upgraded to a new coding system for medical billing, moving the city one step closer to becoming totally paperless.    These technologies will enhance people’s lives and will…